Paroxysmal Supraventricular Tachycardia (PSVT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Paroxysmal supraventricular tachycardia (PSVT) is a type of abnormal heart rhythm known as an arrhythmia characterized by sudden, unpredictable episodes where the heart rate often exceeds 150-200 beats per minute. These episodes can vary in duration, ranging from seconds to days. These episodes typically end abruptly, although gradual disappearance can occur in certain cases. In individuals without overt heart disease, both children and adults may experience chest discomfort due to the sensation of a rapidly beating heart. After an episode, this discomfort may persist in a milder form for a period. This discomfort may be related to myocardial ischemia in older patients with heart disease. Dyspnea, or shortness of breath, can also be a prominent symptom, particularly in patients with pre-existing left ventricular dysfunction, as poor forward cardiac output can worsen pulmonary congestion. PSVT falls into the narrow QRS complex tachycardias category with a regular ventricular response, distinguishing it from conditions like multifocal atrial tachycardia, atrial fibrillation, and atrial flutter. Supraventricular tachycardias (SVTs) are classified based on the origin of the rhythm and whether the rhythm is regular or irregular. Several factors increase the risk of developing PSVT, including alcohol use, caffeine consumption, illicit drug use, and smoking. Symptoms of PSVT often manifest suddenly and can last a few minutes to several hours. These symptoms may include anxiety, a feeling of chest tightness, palpitations (an awareness of the heartbeat, often with an irregular or rapid rate), a rapid pulse, and shortness of breath. In some patients, PSVT may have minimal or no symptoms. In children and infants, persistent PSVT can lead to tachycardia-induced cardiomyopathy, characterized by symptoms such as left ventricular failure, failure to thrive, and fainting. Severe, rapid, or hemodynamically unstable episodes of PSVT can potentially trigger conditions like myocardial infarction, ventricular tachyarrhythmias, and cardiac arrest. The first-line drug treatment for PSVT is adenosine, which is considered a benign arrhythmia. Adenosine and calcium channel blockers have shown promise in safety and efficacy. Adenosine has a relatively short half-life and acts quickly. However, it is associated with higher drug costs, unpleasant side effects, and a higher likelihood of arrhythmia recurrence.

Thelansis’s “Paroxysmal Supraventricular Tachycardia (PSVT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Paroxysmal Supraventricular Tachycardia (PSVT) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Paroxysmal Supraventricular Tachycardia (PSVT) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Paroxysmal Supraventricular Tachycardia (PSVT) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Paroxysmal Supraventricular Tachycardia (PSVT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033